Ajanta Pharma signs pact with Biocon for Semaglutide

[ad_1] Ajanta Pharma has entered into an in-licensing agreement with Biocon for Semaglutide. Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia. A GLP-1 receptor agonist, Semaglutide is to improve glycaemic control in adults. In […]

Continue Reading

Ajanta Pharma Board nod for ₹315 cr share buyback

[ad_1] Drugmaker Ajanta Pharma’s board of directors has approved a ₹315 crore share buyback proposal of the company. The company has proposed buyback, through the tender offer process, of 22,10,500 equity shares of face value of ₹2 each at a price of ₹1,425 per share. It said the total pay-out towards the buyback will not […]

Continue Reading